Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$12.9 million.

  • Janux Therapeutics' Free Cash Flow fell 47398.05% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71.4 million, marking a year-over-year decrease of 8877.11%. This contributed to the annual value of -$44.2 million for FY2024, which is 1574.06% up from last year.
  • Janux Therapeutics' Free Cash Flow amounted to -$12.9 million in Q3 2025, which was down 47398.05% from -$24.3 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Free Cash Flow registered a high of $5.4 million during Q1 2021, and its lowest value of -$24.3 million during Q2 2025.
  • Its 5-year average for Free Cash Flow is -$11.5 million, with a median of -$12.5 million in 2022.
  • As far as peak fluctuations go, Janux Therapeutics' Free Cash Flow crashed by 58159.51% in 2021, and later soared by 8147.63% in 2024.
  • Over the past 5 years, Janux Therapeutics' Free Cash Flow (Quarter) stood at -$11.1 million in 2021, then fell by 25.73% to -$14.0 million in 2022, then grew by 25.43% to -$10.4 million in 2023, then crashed by 60.97% to -$16.8 million in 2024, then increased by 22.77% to -$12.9 million in 2025.
  • Its last three reported values are -$12.9 million in Q3 2025, -$24.3 million for Q2 2025, and -$17.4 million during Q1 2025.